BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Subscribe

« Back to Dashboard

Details for Patent: ➤ Subscribe

Title: Potassium salt of S-omeprazole
Abstract:The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-ben zimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Inventor(s): Kronstrom; Anders (Stockholm, SE), Leander; Eva (Skiptvet, NO), Mattson; Anders (Taby, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Filing Date:Feb 14, 2002
Application Number:10/076,711
Claims:1. The potassium salt of S-omeprazole, wherein the compound is characterized by the following peaks in its X-ray powder diffractogram:

2. A process for the preparation of the potassium salt of S-omeprazole of claim 1, which process comprises the following steps: a) oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimi dazole into S-omeprazole in an organic solvent; b) converting the S-omeprazole into the corresponding potassium salt of S-omeprazole by treating the S-omeprazole with a potassium source; and c) isolating the potassium salt of S-omeprazole thus obtained.

3. The process according to claim 2, wherein the organic solvent used in step a) is toluene.

4. The process according to claim 2 or 3, wherein the potassium source used in step b) is methanolic potassium methoxide or methanolic potassium hydroxide.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: